{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=21",
    "query": {
      "condition": "Genetic Change",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1795,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T16:22:58.932Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01434511",
      "title": "Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "OBI-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2011-10-03",
      "completion_date": "2013-07-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434511"
    },
    {
      "nct_id": "NCT06961565",
      "title": "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NF1 Mutation",
        "Neurofibroma Plexiform",
        "Neurofibroma, Plexiform",
        "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)",
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "PAS-004 Tablets",
          "type": "DRUG"
        },
        {
          "name": "PAS-004 Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pasithea Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-05-30",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06961565"
    },
    {
      "nct_id": "NCT06360211",
      "title": "A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer",
        "EGFR Mutation",
        "HER2 Mutation",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BAY2927088",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2024-04-17",
      "completion_date": "2024-06-28",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06360211"
    },
    {
      "nct_id": "NCT07172321",
      "title": "A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-08049820 MR1",
          "type": "DRUG"
        },
        {
          "name": "PF-08049820 MR2",
          "type": "DRUG"
        },
        {
          "name": "PF-08049820 IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-09-05",
      "completion_date": "2025-10-29",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07172321"
    },
    {
      "nct_id": "NCT01892371",
      "title": "Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FLT3 Gene Mutation Negative",
        "FLT3 Internal Tandem Duplication Positive",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2013-11-12",
      "completion_date": "2023-02-07",
      "has_results": true,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892371"
    },
    {
      "nct_id": "NCT05226507",
      "title": "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Ovarian Clear Cell Tumor",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Endometrioid Tumor",
        "ARID1A Gene Mutation"
      ],
      "interventions": [
        {
          "name": "NXP800",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvectis Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2021-12-31",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05226507"
    },
    {
      "nct_id": "NCT01826487",
      "title": "Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophies",
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, X-Linked",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "Ataluren",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "16 Years",
        "sex": "MALE",
        "summary": "7 Years to 16 Years · Male only"
      },
      "enrollment_count": 230,
      "start_date": "2013-03-26",
      "completion_date": "2015-08-20",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01826487"
    },
    {
      "nct_id": "NCT02758626",
      "title": "Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "ataluren",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-11",
      "completion_date": "2021-02-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02758626"
    },
    {
      "nct_id": "NCT04793958",
      "title": "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Colorectal Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MRTX849",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mFOLFOX6 Regimen",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 461,
      "start_date": "2021-06-24",
      "completion_date": "2026-10-23",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 185,
      "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04793958"
    },
    {
      "nct_id": "NCT02949843",
      "title": "Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EGFR Activating Mutation",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Targeted Molecular Therapy",
          "type": "DRUG"
        },
        {
          "name": "Tyrosine Kinase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2017-03-10",
      "completion_date": "2021-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-11-13T16:22:58.932Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02949843"
    }
  ]
}